Psoriasis is a chronic, inflammatory systemic disease that is characterized by erythematous, scaly patches, or plaques over the skin that occurs due to the hyperproliferation of epidermal keratinocytes. 1,2 The 5-FU is an antimetabolite that inhibits deoxyribonucleic acid synthesis, as well as ribonucleic acid processing and therefore, decreases epidermal proliferation. 3,4 It has been widely used topically, intravenously, 5 and intralesionally in various concentrations (0.5%, 1%, and 5%) in various dermatological 6 and non-dermatological diseases. 7,8 The role of neurocutaneous pathways in the pathogenesis of psoriasis has been suggested based on some reports of improvement of plaque psoriasis after injuries that compromised some branches of the peripheral nervous system. 9,10 BTX injections have been reported for the treatment of numerous dermatological conditions, such as Keloids, hidradenitis suppurativa, and folds dermatitis. 11 The advantage of intralesional is that it allows higher drug concentration in the lesion for a longer duration in comparison with topical treatment while avoiding the systemic adverse effects of these toxic drugs. 12 To study the efficacy and safety of BTX and intralesional 5-fluorouracil in patients with mild-to-moderate chronic plaque psoriasis and to access clinical improvement based on clinical photographs.